Novo Nordisk is set to launch an affordable authorized copy of its diabetes medication Ozempic, named Extensior, in South Africa on July 27. This launch, in partnership with Acino, aims to improve access to the drug, which uses the same semaglutide ingredient and manufacturing process as Ozempic but is offered at a lower price. The demand for GLP-1 drugs has surged in the region, leading to a grey market for unregulated alternatives, prompting the need for this affordable option. Regulators and the companies involved are focused on ensuring high-quality standards while addressing patient accessibility.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://pharma.economictimes.indiatimes.com/news/pharma-industry/novo-nordisk-to-launch-lower-cost-ozempic-copy-in-south-africa/132472542
